Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

A European regulatory committee has rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher In this article, we are ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and ...

VIG's recent rebalancing impacts its holdings, yield, and dividend growth streak. Read here for a comparison with SPY, DGRO, ...

Eli Lilly LLY has outperformed the market over the past 20 years by 6.51% on an annualized basis producing an average annual ...

Despite five hours of streamed casting announcements, there are still several characters and actors fans are surprised won’t ...

LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since ...

Through Synapticure, patients will be able to use LillyDirect to find in-person Alzheimer’s specialists or to connect with ...

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly ...